Survey among healthcare professionals treating patients with metastatic breast cancer in selected European countries to evaluate their knowledge on management of hyperglycemia when using alpelisib

First published: 20/07/2021

Last updated: 03/06/2025

Study Finalised

Administrative details

EU PAS number

EUPAS42022

Study ID

46588

DARWIN EU® study

No

Study countries

Austria

Croatia

Finland
Italy
Luxembourg
Netherlands
Norway
Poland
Slovenia
Spain
Sweden

Study description

In the EU/EEA Piqray (alpelisib) is indicated in combination with fulvestrant for postmenopausal women and men, with HR-positive HER2-negative, locally advanced or metastatic breast cancer (MBC) with PIK3CA mutation after disease progression, following endocrine monotherapy. Hyperglycemia is an expected effect of PI3K inhibition.

To minimize the risk of hyperglycemia, Piqray was approved with a requirement for additional risk minimization measure using an educational material for oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA, containing guidance for the management of hyperglycemia.

The Piqray European Risk Management Plan (RMP) required Novartis to conduct a Post-authorisation Safety Study (PASS) to assess the effectiveness of the educational material. This study was designed and conducted in accordance with Good Pharmacovigilance Practices Modules VIII and XVI for Category 3 PASS.

This was a multinational, non-interventional, cross-sectional survey among HCPs based in the EU/EEA who prescribe Piqray.

The primary objective of the survey was to assess the knowledge of HCPs who prescribe Piqray, specifically regarding their understanding and management of hyperglycemia in patients who are being treated with Piqray.

As per RMP requirement, the survey endeavored to collect a minimum of 100 completed surveys. HCPs were recruited from a targeted population of those who prescribe Piqray and were included in the distribution lists for the Piqray Prescriber’s/HCP Guide for hyperglycemia.
Recruitment took place after at least 6 months following reimbursement and launch of Piqray in each participating country.
A web-based survey was used in all countries.
Data collected included receipt and reading of the educational material, and knowledge of key messages included in the material.
Follow-up reminders were sent to non-respondents to support achieving the target sample size and reducing the impact of selection bias.

Study status

Finalised

Research institutions and networks

Institutions

Novartis Pharmaceuticals

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Novartis Clinical Disclosure Officer
trialandresults.registries@novartis.com

Study contact

trialandresults.registries@novartis.com

Primary lead investigator

Novartis Clinical Disclosure Officer

Primary lead investigator

Study timelines

Date when funding contract was signed
Actual: 07/04/2021

Study start date
Planned: 28/02/2022

Actual: 28/02/2022

Data analysis start date
Planned: 30/12/2024

Actual: 05/06/2024

Date of final study report
Planned: 31/05/2025

Actual: 25/04/2025

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Novartis Pharma AG

Study protocol

byl719c2005--protocol_12-_Redacted.pdf (1.76 MB)

byl719c2005-01--protocol amendment_Redacted.pdf (2.14 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Other study registration identification numbers and links

BYL719C2005

NCT05073120

ClinicalTrials.gov registration form for BYL719C2005

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Study type:

Non-interventional study

Scope of the study:

Other

If ‘other’, further details on the scope of the study

Assess the effectiveness of HCP educational materials

Data collection methods:

Primary data collection

Main study objective:

Assess HCPs’ knowledge and understanding of the key information included in the Piqray Prescriber’s/HCP Guide for hyperglycemia, including:

- Risk of hyperglycemia and its potential risk factors;
- Signs and symptoms of hyperglycemia;
- Recommendations for monitoring for hyperglycemia prior to and during treatment with Piqray;
- Recommendations for managing hyperglycemia during treatment with Piqray.

Study Design

Non-interventional study design

Cross-sectional

Study drug and medical condition

Medicinal product name

PIQRAY

Study drug International non-proprietary name (INN) or common name

ALPELISIB

Anatomical Therapeutic Chemical (ATC) code

(L01EM03) alpelisib

alpelisib

Population studied

Age groups

- **Adult and elderly population (≥18 years)**
  - Adults (18 to < 65 years)
    - Adults (18 to < 46 years)
    - Adults (46 to < 65 years)
  - Elderly (≥ 65 years)
    - Adults (65 to < 75 years)
    - Adults (75 to < 85 years)
    - Adults (85 years and over)

Estimated number of subjects

103

Study design details

Outcomes

A composite based on the percentages of HCPs with correct responses to questions in the composite regarding the information below.
- Risk of hyperglycemia and its potential risk factors;
- Signs and symptoms of hyperglycemia;
- Recommendations for monitoring hyperglycemia prior to and during treatment with Piqray;
- Recommendations for managing hyperglycemia during treatment with Piqray;
- Assess HCPs' reported levels of receipt, and reading, of the Piqray Prescriber's/HCP Guide for hyperglycemia;
- Assess HCPs' knowledge levels for each survey question regarding knowledge of, and management of, hyperglycemia;
- Assess the primary source from which HCPs learned about the messages included in the Piqray Prescriber's/HCP Guide for hyperglycemia.

Data analysis plan

Survey details (e.g. number of invited HCPs, number and percentage of responding HCPs, number and percentage of eligible vs. ineligible HCPs, and number and percentage of HCPs with partially vs. fully completed surveys) and analysis sets were described overall and by country Respondent characteristics/covariates were summarized overall and by country.
Frequencies, percentages, and corresponding 95% 2-sided CI were used to summarize primary and secondary endpoints overall and by country.
For the primary endpoint, the point estimate of the weighted average composite percentage of HCPs who provide correct responses to key questions was estimated and assessed against the 70% threshold.

Summary results

In this study, success criteria on the primary endpoint is defined as a weighted composite knowledge level of at least 70% across key questions.
This endpoint was designed to assess overall knowledge retention and

comprehension among Health Care Professionals.
Overall, a composite score of 81.3% (95% CI: 79.1-83.4) was achieved by Health Care Professionals, thereby meeting the primary objective.

Documents

Study report

CBYL719C2005_Non-Interventional Study Final Report_V1.0_25Apr2025_23 May 2025_Redacted.pdf (9.86 MB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

Survey among healthcare providers

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No